Rory Budihandojo - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Rory Budihandojo


Rory Budihandojo
Director, Quality Systems Audit
Boehringer Ingelheim Shanghai Pharmaceuticals

Rory Budihandojo is the director of quality systems audit at Boehringer Ingelheim Shanghai Pharmaceuticals. He has more than 20 years of worldwide pharmaceutical experience (including Pfizer, GSK, Schering Plough) with responsibilities in R&D, manufacturing (API and finished dosage), QA, IT, pharmaceutical technology, and quality audit. He performed method, process, facility, utility, equipment, and computer validation, as well as GMP auditing of contract manufacturers, suppliers, and internal audits. He has validated chromatography, LIMS, PLC, SCADA, DCS, DMS, BAS, ERP, SAP, change-control systems, and more. 

He was a member of PhRMA and PDA CSV Committee, and a founding member of GAMP Americas, and now serves as the vice-chairman and as a global GAMP Council member. He has published several articles in computer validation and was the lead author of PDA Technical Report No. 31. He serves on the editorial board of Pharmaceutical Technology, BioPharm International, Pharma Magazine, Pharm Tech Europe, and Pharmaceutical Engineering. He has a diploma in electronics, and degrees in chemistry and mathematics.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here